Betta Pharmaceuticals Co., Ltd. Class A

Betta Pharmaceuticals Co., Ltd. Class A

SSZSE:300558
43.25
CNY
-1.66
(-3.70%)
0.59EPS
79.80P/E
21.37BMarket Cap
Apr 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.35
1.96
2.54
2.83
2.55
3.08
3.9
4.63
5.39
5.72
5.86
6.9
8.63
9.02
Basic EPS, GAAP
0.5
0.75
0.96
1.01
0.64
0.42
0.58
1.5
0.92
0.35
0.83
0.96
0.73
0.63
Free Cash Flow per Basic Share
0.47
0.3
0.7
0.31
-0.76
-0.83
-0.16
-0.1
-0.56
-1.69
-0.43
0.2
0.7
- -
Dividend per Share
0.08
0.13
- -
0.01
0.19
0.21
0.24
0.3
0.33
0.34
0.26
0.36
0.36
0.3
Book Value per Share
2.06
1.49
2.47
4.8
5.12
5.56
6.14
10.02
10.98
11.62
12.55
13.32
15.68
15.44
Tangible Book Value per Share
1.48
0.99
1.98
4.41
2.03
1.9
1.58
4.73
4.12
4.25
4
4.78
7.98
8.27
Basic Weighted Avg Shares
357
359
360
365
403
397
398
404
416
415
419
419
418
422
Sales/Revenue/Turnover
481
704
915
1,035
1,026
1,224
1,554
1,870
2,246
2,377
2,456
2,892
3,609
3,802
Operating Margin (%)
39.02
40.59
39.18
35.13
25.58
15.87
20.06
23.66
16.98
8.77
13.52
17.24
16.15
16.8
Depreciation Expense
15
17
18
19
68
99
143
155
174
254
303
372
551
- -
Net Income, GAAP
178
269
345
369
258
167
231
606
383
145
348
403
305
267
Effective Tax Rate (%)
13.69
13.34
13.87
13.33
13.72
10.34
15.24
9.84
2.66
- -
- -
1.82
30.93
37.6
Profit Margin (%)
37.11
38.23
37.75
35.63
25.11
13.63
14.85
32.42
17.06
6.12
14.17
13.92
8.46
7.01
Working Capital
166
175
422
1,098
-11
-176
87
1,405
765
-372
-277
-624
-339
-9
LT Debt
15
11
85
- -
100
280
280
6
6
663
1,824
1,554
1,527
1,216
Total Equity
319
543
894
1,929
2,067
2,244
2,469
4,145
4,686
4,958
5,351
5,666
6,668
6,548
Return on Invested Capital (%)
58.95
54.93
38.81
21.35
8.8
6.15
7.5
16.6
8.54
- -
- -
4.97
3.36
2.94
Return on Capital (%)
68.23
60.95
44.88
25.46
12.45
7.34
9.22
17.82
9.08
- -
- -
5.87
4.42
3.86
Return on Common Equity (%)
74.21
63.77
48.51
26.22
12.96
7.79
9.84
18.37
8.8
3.09
6.89
7.44
5.02
4.4

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
806
1,182
1,194
LT Borrowings
1,703
1,250
1,215
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
421
421
423
Market Capitalization
18,344
27,377
21,370

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,670
1,742
2,094
Cash, Cash Equivalents & STI
510
456
706
Accounts Receivable, Net
512
625
663
Inventories
352
363
396
Total Current Liabilities
1,686
2,055
2,102
Payables & Accruals
- -
- -
- -
ST Debt
806
1,182
1,194
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.98%
10.07%
17.68%
Free Cash Flow
17.71%
143.62%
252.47%
Net Income, GAAP
17.45%
6.4%
-24.15%
Sales/Revenue/Turnover
15.07%
14.36%
24.81%
Total Cash Common Dividend
189.45%
6.42%
-0.08%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
736
765
844
547
2,892
2025
918
814
- -
892
3,609
2026
1,040
936
934
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.3
0.46
-0.03
0.96
2025
0.24
0.09
- -
-0.03
0.73
2026
0.56
0.16
-0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.2
0.02
0.11
0.36
2025
0.05
0.24
- -
0.04
0.36
2026
0.04
0.19
0.04
- -
- -

Company Description

CEO
Lie Ming Ding
Full Time Employees
1,785
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 355, Xingzhong Road Hangzhou ZH China 311100
IPO Date
Nov 9, 2016
Business
Betta Pharmaceuticals Co., Ltd. (300558.SZ) is a China-based biopharmaceutical company primarily engaged in the research, development, production and commercialization of innovative oncology drugs targeting malignant tumors, including non-small cell lung cancer (NSCLC), renal cell carcinoma and other solid tumors. Founded in 2003 and headquartered in Hangzhou, Zhejiang Province, the company integrates end-to-end operations across R&D, manufacturing and sales, with over 1,700 employees and R&D centers in Hangzhou and Beijing; it listed on the Shenzhen Stock Exchange in November 2016. Betta offers a portfolio of marketed products including Icotinib hydrochloride (Conmana®), China's first domestically developed small molecule EGFR tyrosine kinase inhibitor (TKI) approved in 2011 for first-line treatment of EGFR-mutated locally advanced or metastatic NSCLC; Ensartinib hydrochloride (Ensacove®), a next-generation ALK inhibitor approved in China in 2020 for ALK-positive advanced NSCLC and receiving U.S. FDA approval in December 2024 as the first globally marketed small-molecule lung cancer targeted drug led by a Chinese firm; Bevacizumab biosimilar (MIL60), approved in November 2021 for metastatic colorectal cancer and advanced NSCLC with additional indications added in 2022; Befotertinib (Surmana®), a third-generation EGFR-TKI approved in May 2023 for T790M-mutated NSCLC post-first-generation TKI resistance; and Vorolanib (CM082), a multi-target kinase inhibitor approved in June 2023 in combination with everolimus for advanced renal cell carcinoma progressing after TKI therapy. The company's pipeline encompasses over 20 programs in clinical stages, such as bispecific antibody MCLA-129 targeting EGFR/c-Met for advanced solid tumors, PD-L1 inhibitor BPI-371153, HIF-2α inhibitor BPI-452080, TEAD inhibitor BPI-460372 and EGFR degrader CFT8919, alongside investigational candidates like EYP-1901 for ophthalmic conditions using vorolanib with Durasert delivery technology. Betta primarily serves oncologists, hospitals and patients in China, with expanding global ambitions highlighted by Ensartinib's U.S. approval, and maintains strategic partnerships including collaborations with C4 Therapeutics in May 2023, Agenus for PD-1/CTLA-4 antibodies since 2020, Xcovery as a subsidiary for ALK inhibitors since 2014-2017, and prior investments in Mabworks, Anew Pharma, Repugene and others to bolster biologics and targeted therapies. Recent developments underscore Betta's R&D momentum, with R&D spending averaging over 40% of revenues and initiatives like the Betta Dreamworks incubator fostering external innovation.